| # | Title | Journal | Year | Citations |
|---|
| 1 | Myocarditis in the Setting of Cancer Therapeutics | Circulation | 2019 | 278 |
| 2 | JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis | Brain | 2018 | 169 |
| 3 | Immune-mediated necrotizing myopathy: clinical features and pathogenesis | Nature Reviews Rheumatology | 2020 | 131 |
| 4 | Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial | Lancet Neurology, The | 2019 | 91 |
| 5 | Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis | JAMA Cardiology | 2021 | 64 |
| 6 | Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients | PLoS ONE | 2020 | 54 |
| 7 | Biomarkers in Inflammatory Myopathies—An Expanded Definition | Frontiers in Neurology | 2019 | 48 |
| 8 | Sequestosome‐1 (p62) expression reveals chaperone‐assisted selective autophagy in immune‐mediated necrotizing myopathies | Brain Pathology | 2020 | 42 |
| 9 | Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial | Lancet Rheumatology, The | 2021 | 32 |
| 10 | Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept | | 2022 | 29 |
| 11 | Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective | Kidney International | 2018 | 18 |
| 12 | Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients | Autoimmunity Reviews | 2020 | 14 |
| 13 | Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis | Brain Pathology | 2020 | 13 |
| 14 | 256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021 | Neuromuscular Disorders | 2022 | 13 |
| 15 | NanoString technology distinguishes anti‐TIF‐1γ+ from anti‐Mi‐2+ dermatomyositis patients | Brain Pathology | 2021 | 11 |
| 16 | Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice | Journal of Neuromuscular Diseases | 2019 | 7 |
| 17 | Expanding the spectrum of HIV-associated myopathy | Journal of Neurology, Neurosurgery and Psychiatry | 2019 | 7 |
| 18 | Endoplasmic reticulum‐stress and unfolded protein response‐activation in immune‐mediated necrotizing myopathy | Brain Pathology | 2022 | 7 |
| 19 | Correlation between Ultra-Wide-Field Retinal Imaging Findings and Vascular Supra-Aortic Changes in Takayasu Arteritis | Journal of Clinical Medicine | 2021 | 5 |
| 20 | Germinal Center T follicular helper (GC-Tfh) cell impairment in chronic HIV infection involves c-Maf signaling | PLoS Pathogens | 2021 | 4 |
| 21 | Brain Biopsy for Neurological Diseases of Unknown Etiology in Critically Ill Patients: Feasibility, Safety, and Diagnostic Yield | Critical Care Medicine | 2022 | 4 |
| 22 | Treat to target in Behcet's disease: Should we follow the paradigm of other systemic rheumatic diseases? | Clinical Immunology | 2023 | 4 |
| 23 | Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib | Brain | 2019 | 3 |
| 24 | Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection | | 2022 | 3 |
| 25 | Comment on: Is early-onset primary Sjögren’s syndrome a worse prognosis form of the disease? Reply | Rheumatology | 2019 | 2 |
| 26 | Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis | Brain | 2019 | 1 |
| 27 | (null) | | 2020 | 0 |
| 28 | (null) | | 2020 | 0 |
| 29 | (null) | | 2020 | 0 |
| 30 | (null) | | 2020 | 0 |
| 31 | The Phenotype of Mixed Connective Tissue Disease Patients Having Associated Interstitial Lung Disease | SSRN Electronic Journal | 0 | 0 |
